Arformoterol Tartrate Inhalation Solution
Product Images NDC 73289-0072

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate Inhalation Solution (NDC 73289-0072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aucta Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecule (Bro01 0036 01)

Chemical structure diagram depicting Arformoterol Tartrate, showing the molecular arrangement of the active ingredient in the inhalation solution.*

FDA Label Image

Ifu-fig-1 (Bro01 0036 05)

Illustration diagram showing a person holding a vial or a small container, demonstrating a twisting motion arrow around the cap, indicating how to open or prepare the inhalation solution device for use.*

FDA Label Image

Ifu-fig-2 (Bro01 0036 06)

An instructional illustration showing a hand squeezing a tube to dispense liquid into a reservoir. The reservoir is labeled "RESERVOIR." This diagram is likely part of usage instructions for the inhalation solution.*

FDA Label Image

Ifu-fig-3 (Bro01 0036 07)

A black and white line drawing illustrating a mouthpiece attachment for an inhalation device. The diagram labels the mouthpiece component, showing its position relative to the main inhalation device body and the connected tubing.*

FDA Label Image

Ifu-fig-4 (Bro01 0036 08)

An instructional illustration showing a face mask designed for respiratory inhalation. The image highlights the proper fitting of the mask on the face, positioned near an inhalation device.*

FDA Label Image

Ifu-fig-5 (Bro01 0036 09)

An illustration showing a compressor device labeled 'COMPRESSOR' with a connected tube labeled 'TUBING'. The image depicts the setup for respiratory inhalation use, likely related to the administration of an inhalation solution such as Arformoterol Tartrate Inhalation Solution.*

FDA Label Image

Ifu-fig-6 (Bro01 0036 10)

An instructional illustration showing a person using a respiratory inhalation device by placing the mouthpiece in their mouth, demonstrating the proper method of inhalation for a medication solution.*

FDA Label Image

Carton-30ct (Carton 30ct)

Packaging label for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL by Aucta Pharmaceuticals, Inc. The label indicates the solution is for oral inhalation only and comes in 30 x 2 mL sterile unit-dose vials. Storage instructions note to keep refrigerated or store at room temperature up to 30°C (86°F), with protection from light. The label includes serialization information and a barcode area.*

FDA Label Image

Carton-60ct (Carton 60ct)

Packaging label for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, a respiratory inhalation solution by Aucta Pharmaceuticals, Inc. The label indicates single unit-dose vials in a 60-count package, with usage instructions, storage directions to keep refrigerated or store at room temperature for up to 6 weeks, and a barcode. The product is for oral inhalation only and prescription use.*

FDA Label Image

Foil-card (Foilcard)

Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL label by Aucta Pharmaceuticals, Inc. The label includes dosage instructions noting one unit-dose vial per dose, storage guidelines recommending refrigeration, and warnings to keep out of reach of children and use by prescription only. The product is supplied as a solution for respiratory inhalation and is packaged in four 2 mL sterile unit-dose vials.*

FDA Label Image

Foil-single (Foilsingle)

Label for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL sterile unit-dose vial by Aucta Pharmaceuticals, Inc. It includes product dosage strength, administration instructions, storage requirements, warnings, and manufacturer details on a white background with green and blue text accents.*

FDA Label Image

Trial-fig (Trial Fig)

Two line graphs titled 'Mean Change in FEV1 Over Time for Clinical Trial A' at Week 0 (Day 1) and Week 12 showing mean change from baseline FEV1 (L) on the Y-axis and hours postdose on the X-axis. Each graph compares placebo and 15 mcg arformoterol tartrate inhalation solution BID, with data points plotted over 12 hours postdose, indicating higher mean improvements with the arformoterol solution compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.